Events & Presentations
Date | Event Details |
---|---|
Aug 4, 2022 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2022 Third Quarter Results
Prepared Remarks 241.8 KB
|
Jun 22 - Jun 26, 2022
|
The International Liver Congress™ 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL)
EASL 2022 AROAAT2002 1.5 MB
EASL 2022 JNJ-3989 MIDD 11.8 MB
EASL 2022 JNJ-3989 REEF-1 4.1 MB
EASL 2022 JNJ-3989 REEF-2 1.2 MB
Title: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study Title: Understanding the Dynamics of HBsAg Decline Through Model-informed Drug Development (MIDD) of siRNA and CAM-N for the Treatment of Chronic Hepatitis B (CHB) Virus Infection Title: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study Title: Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency |
Jun 13 - Jun 16, 2022
|
Goldman Sachs 43rd Annual Global Healthcare Conference
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
Jun 8, 2022 8:30 AM EDT
|
Jefferies Healthcare Conference
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
May 26, 2022 10:00 AM EDT
|
Pulmonary R&D Day
View Presentation 16.6 MB
New York
|
May 25, 2022 12:15 PM EDT
|
UBS Global Healthcare Conference 2022
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |
May 17, 2022 4:35 PM EDT
|
2022 RBC Capital Markets Global Healthcare Conference
Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals |
May 13 - May 18, 2022
|
2022 American Thoracic Society (ATS) International Conference
ATS 2022 MUC5AC 2 MB
ATS 2022 RAGE 2.2 MB
Title: Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation
Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals Title: Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals |
May 12, 2022 1:40 PM EDT
|
BofA Securities 2022 Healthcare Conference
Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals |
May 10, 2022 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2022 Second Quarter Results
Prepared Remarks 260.5 KB
|